(Stanford University Medical Center) A new retrospective study of the health records of prostate cancer patients supports an association between androgen deprivation therapy and future risk of dementia.
In a study that included more than 10,000 men with nonmetastatic prostate cancer, use of androgen deprivation therapy (ADT) was associated with a significantly increased risk of acute kidney injury, with variations observed with cer...
Reducing testosterone levels with androgen deprivation therapy, or A.D.T., more than doubles the risk of dementia.
Men treated with androgen deprivation therapy - a hormone therapy - for prostate cancer may be more than twice as likely to develop dementia, study finds.
Androgen Deprivation Therapy, a common hormone therapy to treat prostate cancer, may double a man's risk of dementia, regardless of his age, Penn Medicine researchers reported.